To test this hypothesis, we added imatinib [32,33] (Gleevec, Novartis, Basel, Switzerland), a PDGFR inhibitor, to the re-initiated IFN-α treatment, which resulted in significant inhibition of tumor growth and angiogenesis. The gene discussed is PDGFRB; the disease is neoplasm.